Killer cocktail fights brain cancer

November 25, 2013
The tumor (dark region, left) in this mouse brain was eradicated (arrowhead, right) with a novel drug cocktail, according to a Journal of Experimental Medicine study. Credit: vom Berg et al., 2013

A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

Glioblastoma is the most aggressive form of , and current treatments only modestly prolong patient survival. Immune cells called T cells have the capacity to attack and kill , but tumors can counteract this attack by creating an environment that dampens T cell activity. T cells have ways of limiting their own activation (and thus autoimmunity), one of which is to express inhibitory cell surface proteins upon activation. In other cancer models, strategies to block these inhibitory proteins have been shown to reinvigorate T cell activation and thus promote .

Burkhard Becher and colleagues at the University of Zurich now show that a two-pronged approach is most effective against glioblastoma. They simultaneously injected mice with a T cell–boosting protein called interleukin-12 and a drug that blocks the inhibitory receptor CTLA-4. The cocktail eradicated the animals' brain tumors.

Whether these findings will pave the way for a new therapeutic approach to treat glioblastoma in humans awaits clinical trials.

Explore further: New immuno-therapy for malignant brain tumors

More information: vom Berg, J., et al. 2013. J. Exp. Med. DOI: 10.1084/jem.20130678

Related Stories

New immuno-therapy for malignant brain tumors

November 25, 2013

Animal experiments show that it is relatively easy to treat cancer in the early stages. However, it is far more difficult to successfully treat advanced cancer. Treatment of brain tumors is particularly challenging because ...

Researchers discover how cancer 'invisibility cloak' works

October 28, 2013

Researchers at National Jewish Health have discovered how a lipid secreted by cancer tumors prevents the immune system from mounting an immune response against it. When lysophosphatidic acid (LPA) binds to killer T cells, ...

Finding antitumor T cells in a patient's own cancer

November 13, 2013

Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer ...

Recommended for you

Dogs detect breast cancer from bandage: researchers

March 24, 2017

Dogs can sniff out cancer from a piece of cloth which had touched the breast of a woman with a tumour, researchers said Friday, announcing the results of an unusual, but promising, diagnostic trial.

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.